365DisInFx™ Commercial UV Disinfection Lighting
Different Solutions for Different Needs
Current’s UV disinfection lighting products operates below the human health exposure limits determined by IEC 62471 Photobiological Safety for Lamps and Lamp Systems standard and the American Conference of Governmental Industrial Hygienists (ACGIH®) guidelines.

Air Disinfection
UVC solutions can help reduce viruses in air. Based on testing, 365DisInFx® LPU Gen2 devices are predicted to provide 90% inactivation of aerosolized SARS-CoV-2 (the virus that causes COVID-19) in the first hour or less of exposure when used as directed.1
Quantity & Spacing

Surface Disinfection
UVA solutions can help reduce bacteria and fungi on surfaces. Our in vitro testing with eight hours of exposure has shown significant reductions in common pathogens associated with hospital-acquired infections (HAIs), such as MRSA, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, Candida albicans and auris.2
Explore the products.
* If combining two or more UV solutions, please consult a trained product application representative to ensure the total irradiance (UV dose) does not exceed recommended human exposure limits. To the extent UV solutions are combined, it may impact inactivation rates.

COMPLIANT
Meets IIEC 62471 Photobiological Safety for Lamps and Lamp Systems standard and American Conference of Governmental Industrial Hygienists (ACGIH®) TLVs® for human exposure to UV. UVA products are UL 1598 certified and UVC are UL 8802 certified.

CONTINUOUS
Flexible LED solutions for 24 hour occupancy providing an added layer of protection along with masks, hygiene and social distancing.
Designed to operate below human health exposure limits of IEC 62471 Photobiological Safety for Lamps and Lamp Systems standard and American Conference of Governmental Industrial Hygienists (ACGIH®).

TEST DRIVEN
Current conducts third party testing to substantiate our claims and validate our predictive models. We continue to expand our testing to verify effectiveness against additional pathogens.*
Current is certified through UL’s Data Acceptance Program (DAP) to perform testing to the IEC 62471 safety standard..
* See “UVC and UVA Testing, Lab Results, Notes and Citations” for supporting details.
Designed for Continuous Use in High Traffic Spaces
At education
At hospitals
At work
At healthcare spaces
At meeting places
At leisure
Inspiration
Make an Informed Decision
- UV radiation can pose a risk of personal injury. Overexposure can result in damage to eyes and bare skin. To reduce risk of overexposure, equipment must be installed in accordance with site planning and application recommendations.
- UV solutions are intended for common high traffic spaces and not recommended for dwellings or home use.
- Installation of the devices should be performed by qualified professionals as detailed in Current’s installation guide
- To allow for occupancy during use, Current products comply with UL 8802 Outline of Investigation for UV Germicidal Equipment and Systems, IEC 62471 Photobiological Safety of Lamps and Lamp Systems standards, and American Conference of Governmental Industrial Hygienists (ACGIH®) TLVs® guidelines over an 8-hour period when installed as directed.
- Current's UV products are meant to be used in conjunction with other protective measures like manual cleaning and the use of proper PPE. They are not a substitute for other measures.
- Current products are not intended to be used as a medical devices.
- When combining two or more UV solutions, whether from Current and/or other manufacturers, please consult a trained product application representative to ensure the total irradiance (UV dose) does not exceed recommended human exposure limits. To the extent UV solutions are combined, it may affect the deactivation rates.
Explore UV Products
Explore UV Products
UVC Test Results
Current has completed room-scale tests of its 365DisInFx® UVC disinfection technology LPU series devices that show reduction of the aerosolized viruses SARS-CoV-21 (the virus that causes COVID-19), and bacteriophage MS22.
Applying photobiological science and mathematical modeling to the results of device testing and published literature, continuous operation of a properly installed array of 365DisInFx® LPU Gen2 devices is predicted to provide 90% (1-log10) inactivation of aerosolized SARS-CoV-2 in the first hour1 or less of exposure and 99% inactivation (2-log10) in 2 hours or less of exposure in most spaces when configured for an 8-hour or greater Permissible Exposure Time (PET) as defined in IEC 62471 – Photobiological Safety of Lamps and Lamp Systems standards at 7 foot head height. Current continues to conduct additional supporting experiments.
1Testing with the SARS-CoV-2 using LPU devices with prototype refractive optics resulted in 90% inactivation of the aerosolized virus within 2 hours. This testing was then used as the basis for photobiological science and mathematical modeling. The test was conducted in an 8-by-20-by-8-foot room equipped with twelve LPU devices using prototype refractive optics, configured for 8-hour Permissible Exposure Time (PET) at head height (7 feet). SARS-CoV-2 Isolate USA-CA1/2020 was used in this testing, and results are expected to be applicable to other SARS-CoV-2 isolates or strains, including B.1.617.2 (Delta) or other Variants of Concern or Interest, as well as to seasonal human coronaviruses.
2Testing with the bacteriophage MS2 resulted in 88% inactivation of the aerosolized virus within 4 hours. The test was conducted in a 10-by-10-by-8-foot room equipped with seven LPU prototype devices, configured for a 4-hour Permissible Exposure Time (PET) at head height. Bacteriophage MS2 is a nonenveloped virus that is commonly used as a surrogate in testing for viruses that are pathogenic to humans. It is particularly useful as a surrogate whereas published scientific testing and literature supports that bacteriophage MS2 is more resistant to UVC than certain enveloped viruses such as coronaviruses and influenza.
UVA Testing, Lab Results & Notes
365DisInFx® UVA disinfection technology was tested using in-vitro methods as described in detail in Citations 1 & 2 below (Livingston, Kvam) which resulted in 99.7% reduction in MRSA on surfaces exposed to 3W/m2 of 365nm UVA over a single 8-hour period. Results of this testing demonstrated significant reduction over a similar exposure period of certain common pathogens including MRSA, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, Candida albicans and auris, associated with Hospital Acquired Infections (HAIs). Photobiological science and mathematical modeling enables us to calculate expected inactivation rates for 24-hour continuous operation of the 365DisInFx® UVA technology.
Notes & Citations:
1 Livingston SH, Cadnum JL, Benner KJ, Donskey CJ (2020) Efficacy of an ultraviolet-A lighting system for continuous decontamination of health care-associated pathogens on surfaces.
Am. J. Infect. Control 48: 337-339.
https://doi.org/10.1016/j.ajic.2019.08.003
- inoculated steel disk carriers, modification of ASTM E-2197-02
- using a benchtop device that delivered the 3W/m² irradiance
2 Kvam E, Benner K (2017) Disinfection via LED Lighting: summary of mechanism and results for 365nm-mediated inactivation of microbes. GE Global Research Technical Information Series 2017GRC0545, GE Confidential (Class 3)
Kvam E, Benner K. Mechanistic insights into UV-A mediated bacterial disinfection via endogenous photosensitizers. Journal of Photochemistry and Photobiology B: Biology. 2020;209:111899. doi:10.1016/j.jphotobiol.2020.111899.
- aqueous cultures were diluted in sterile water and dried onto hydrophilic glass slides
- using a benchtop device that delivered the 3W/m² irradiance
Supporting Literature and Publications
Continuous Disinfecting: The Future of Fighting Hospital Acquired Infections
Fierce Electronics
Mechanistic insights into UV-A mediated bacterial disinfection via endogenous photosensitizers
Journal of Photochemistry and Photobiology B: Biology
American Journal of Infection Control | Brief Report
SHEA Spring 2018 Conference; April 18-20, 2018 | Portland, OR | Livingston S, Cadnum J, Nerandzic M, Donskey CJ